Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) announces the publication of its 2014 Annual Report and 2014 Annual Summary for the fiscal year ended December 31, 2014. The filing, dated February 26, 2015, serves to notify shareholders and the SEC of the availability of these documents and outlines the schedule for the 2015 Annual General Meeting. The unaudited preliminary results for the year were previously announced on February 4, 2015.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced 2014 Annual Report and Preliminary Results announcement. The only specific financial figure disclosed in this text is a fine of RMB 3 billion (approximately £301 million) paid to the Chinese government regarding bribery convictions.
Material Changes and Unusual Items
- Legal Proceedings and Fines: GSK China Investment Co. Ltd. was found guilty of bribing non-government personnel in China. The company paid a fine of RMB 3 billion (£301 million) following a court verdict on September 19, 2014.
- Ongoing Investigations: The Group is subject to extra-territorial anti-bribery and corruption (ABAC) inquiries led by US and UK authorities regarding operations in China and other markets.
- Supply Chain Disruptions: In 2014, the Consumer Healthcare business (specifically Smokers' Health products, alli, and Bactroban) and the Vaccines business (hepatitis vaccines and Boostrix) faced supply constraints.
- Patent Expirations: The filing notes that the US patent for compositions containing the active substances in Seretide/Advair expired in 2010, though a device patent remains until August 2016. Generic competition for this product, which accounts for 18% of Group sales, is a material risk.
Guidance, Outlook, and Management Commentary
The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. Management commentary focuses heavily on risk mitigation strategies rather than financial guidance. Key strategic shifts mentioned include:
- Sales Compensation Model: GSK committed to changing its global sales compensation model from one based on sales targets to one rewarding the quality of interactions with healthcare professionals.
- Payments to HCPs: The company publicly committed to stop various payments to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) by 2016.
- Dividend Schedule: The filing provides specific ex-dividend, record, and payment dates for Q4 2014 through Q3 2015.
Principal Risks and Uncertainties
The filing details extensive risk factors, including:
- Regulatory and Legal: Risks related to product liability, patent litigation, antitrust claims, and compliance with evolving global regulations.
- Intellectual Property: The threat of generic competition following patent expirations, particularly in the US market.
- Product Quality and Safety: Risks of manufacturing non-compliance, adverse events, and the need for robust post-marketing surveillance.
- Supply Chain: Vulnerability to single-source suppliers and regulatory disruptions affecting manufacturing.
- Information Protection: Risks associated with cyber threats and data integrity.
Investor Verification Checklist
- Verify the full financial performance metrics (revenue, net income, EPS) in the 2014 Annual Report and the February 4, 2015 Preliminary Results announcement.
- Review Note 45 ('Legal proceedings') in the 2014 Annual Report for detailed status updates on the China bribery case and US/UK investigations.
- Assess the impact of the Seretide/Advair patent situation and generic entry on future respiratory product revenue.
- Confirm the status of supply chain resolutions for the Consumer Healthcare and Vaccines businesses mentioned as impacted in 2014.
- Monitor the implementation of the new sales compensation model and the cessation of payments to HCPs by 2016.